{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:29:20Z","timestamp":1762601360638,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005881","name":"Hemostasis and Thrombosis Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010941","name":"University of Vermont","doi-asserted-by":"publisher","award":["P20 GM135007"],"award-info":[{"award-number":["P20 GM135007"]}],"id":[{"id":"10.13039\/100010941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.06.020","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:56:54Z","timestamp":1751025414000},"page":"e721-e730.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization Patterns and Outcomes From Iron Chelation Therapy in Elderly Patients With Myelodysplastic Syndromes: A Population Analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-4141","authenticated-orcid":false,"given":"Aneta","family":"Strumilowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-4105","authenticated-orcid":false,"given":"Andrew","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8824-4410","authenticated-orcid":false,"given":"Neil","family":"Zakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-2165","authenticated-orcid":false,"given":"Diego","family":"Adrianzen Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clml.2025.06.020_bib0001","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2025.06.020_bib0002","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1007\/s00277-024-06085-0","article-title":"Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists","volume":"103","author":"Blankstein","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/hematology.2020000103","article-title":"Outpatient transfusions for myelodysplastic syndromes","volume":"2020","author":"Wood","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12185-017-2367-1","article-title":"Iron overload in myelodysplastic syndromes (MDS)","volume":"107","author":"Gattermann","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2025.06.020_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103367","article-title":"Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae","volume":"163","author":"Kim","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2025.06.020_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.critrevonc.2015.11.017","article-title":"New insights into transfusion-related iron toxicity: Implications for the oncologist","volume":"99","author":"Porter","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0007","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/hematology.2020000127","article-title":"Therapy for lower-risk MDS","volume":"2020","author":"Carraway","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2025.06.020_bib0008","article-title":"Past, present and future in low-risk myelodysplastic syndrome","volume":"9","author":"Toprak","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.clml.2025.06.020_bib0009","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41408-022-00765-8","article-title":"Management of patients with lower-risk myelodysplastic syndromes","volume":"12","author":"Brunner","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2025.06.020_bib0010","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2023.2220451","article-title":"Survival gains in myelodysplastic syndromes following a decade of the modern treatment paradigm","volume":"64","author":"Adrianzen-Herrera","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.06.020_bib0011","article-title":"The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"11","author":"Weber","year":"2020","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.clml.2025.06.020_bib0012","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/cncr.31550","article-title":"Iron overload in patients with myelodysplastic syndromes: An updated overview","volume":"124","author":"Moukalled","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2025.06.020_bib0013","first-page":"392","article-title":"Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment","volume":"9","author":"Lyle","year":"2018","journal-title":"J Adv Pract Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.020_bib0014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.2023022501","article-title":"How I treat iron overload in adult MDS","volume":"145","author":"Leitch","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.blre.2018.03.002","article-title":"To chelate or not to chelate in MDS: That is the question!","volume":"32","author":"Zeidan","year":"2018","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.clml.2025.06.020_bib0016","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","article-title":"Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes","volume":"97","author":"Gattermann","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2025.06.020_bib0017","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1080\/10428194.2017.1312385","article-title":"Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study","volume":"58","author":"Messa","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.06.020_bib0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2019.06.002","article-title":"Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions","volume":"141","author":"Leitch","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.020_bib0019","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ejh.12300","article-title":"Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)","volume":"92","author":"Angelucci","year":"2014","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.020_bib0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-012-1594-z","article-title":"Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload","volume":"92","author":"Nolte","year":"2013","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0021","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.leukres.2014.02.003","article-title":"Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes","volume":"38","author":"Delforge","year":"2014","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.clml.2025.06.020_bib0022","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3324\/haematol.2018.212332","article-title":"Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry","volume":"105","author":"Hoeks","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.06.020_bib0023","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","article-title":"Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry","volume":"36","author":"Neukirchen","year":"2012","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0024","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.14825","article-title":"Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis","volume":"179","author":"Leitch","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.020_bib0025","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.leukres.2012.08.001","article-title":"Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis","volume":"36","author":"Leitch","year":"2012","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0026","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.13053","article-title":"The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome","volume":"167","author":"Mainous","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.020_bib0027","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2217\/cer.15.20","article-title":"Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes","volume":"4","author":"Zeidan","year":"2015","journal-title":"J Comp Eff Res"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0028","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1537-2995.2009.02361.x","article-title":"Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices","volume":"50","author":"Raptis","year":"2010","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.clml.2025.06.020_bib0029","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","article-title":"Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies)","volume":"34","author":"Rose","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.clml.2025.06.020_bib0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.leukres.2013.11.004","article-title":"Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry","volume":"38","author":"Lyons","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2025.06.020_bib0031","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.leukres.2017.01.033","article-title":"Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years","volume":"56","author":"Lyons","year":"2017","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0032","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-014-2274-y","article-title":"Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications","volume":"94","author":"Remacha","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.020_bib0033","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2141.2011.08749.x","article-title":"Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes","volume":"154","author":"Roy","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.06.020_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106170","article-title":"Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy","volume":"83","author":"Wong","year":"2019","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0035","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/bjh.19316","article-title":"Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study","volume":"204","author":"Sarocchi","year":"2024","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.020_bib0036","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"issue":"55","key":"10.1016\/j.clml.2025.06.020_bib0037","first-page":"3","article-title":"Updated Overview of the SEER-Medicare Data: Enhanced Content and Applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"8 Suppl","key":"10.1016\/j.clml.2025.06.020_bib0038","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2025.06.020_bib0039","unstructured":"World Health Organization. International classification of diseases for oncology (ICD-O). Third Edition 2013. Available from: http:\/\/www.who.int\/iris\/handle\/10665\/96612."},{"issue":"6","key":"10.1016\/j.clml.2025.06.020_bib0040","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/ejh.13865","article-title":"Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes","volume":"109","author":"Rozema","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2025.06.020_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.752192","article-title":"From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox","volume":"11","author":"Palumbo","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.020_bib0042","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.17612","article-title":"British Society for Haematology guidelines for the management of adult myelodysplastic syndromes","volume":"194","author":"Killick","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.06.020_bib0043","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.09.005","article-title":"Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS","volume":"74","author":"Leitch","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0044","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12185-008-0119-y","article-title":"Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes","volume":"88","author":"Suzuki","year":"2008","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2025.06.020_bib0045","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.leukres.2010.01.018","article-title":"Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines","volume":"34","author":"Santini","year":"2010","journal-title":"Leuk Res"},{"issue":"17","key":"10.1016\/j.clml.2025.06.020_bib0046","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.06.020_bib0047","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.leukres.2014.09.011","article-title":"Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS)","volume":"38","author":"Uno","year":"2014","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0048","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/cam4.283","article-title":"Cardiovascular event-free survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk","volume":"3","author":"Onwudiwe","year":"2014","journal-title":"Cancer Med"},{"issue":"13","key":"10.1016\/j.clml.2025.06.020_bib0049","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1080\/10428194.2019.1622700","article-title":"RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis","volume":"60","author":"Zeidan","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2025.06.020_bib0050","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.leukres.2013.02.021","article-title":"Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines","volume":"37","author":"Davidoff","year":"2013","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.clml.2025.06.020_bib0051","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/ajh.25166","article-title":"Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes","volume":"93","author":"Brunner","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.020_bib0052","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1080\/10428194.2020.1869959","article-title":"Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis","volume":"62","author":"Stein","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0053","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.clml.2025.06.020_bib0054","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1182\/bloodadvances.2023011050","article-title":"Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis","volume":"7","author":"Adrianzen-Herrera","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0055","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1475-6773.2011.01277.x","article-title":"Identifying chronic conditions in Medicare claims data: evaluating the Chronic Condition Data Warehouse algorithm","volume":"46","author":"Gorina","year":"2011","journal-title":"Health Serv Res"},{"issue":"17","key":"10.1016\/j.clml.2025.06.020_bib0056","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.020_bib0057","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/sim.8008","article-title":"Propensity-score matching with competing risks in survival analysis","volume":"38","author":"Austin","year":"2019","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.clml.2025.06.020_bib0058","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2013.09.009","article-title":"When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?","volume":"26","author":"Steensma","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.020_bib0059","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000357","article-title":"Controversies on the Consequences of Iron Overload and Chelation in MDS","volume":"4","author":"Vinchi","year":"2020","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.clml.2025.06.020_bib0060","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1537-2995.2010.02617.x","article-title":"Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients","volume":"50","author":"Oliva","year":"2010","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.clml.2025.06.020_bib0061","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.leukres.2012.11.005","article-title":"Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes","volume":"37","author":"Hartmann","year":"2013","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0062","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2017.08.005","article-title":"A storm in the niche: Iron, oxidative stress and haemopoiesis","volume":"32","author":"Pilo","year":"2018","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0063","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/s12885-021-08259-9","article-title":"The effects of secondary iron overload and iron chelation on a radiation-induced acute myeloid leukemia mouse model","volume":"21","author":"Chan","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.06.020_bib0064","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13046-019-1397-3","article-title":"Iron and leukemia: new insights for future treatments","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.clml.2025.06.020_bib0065","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/bloodadvances.2017010165","article-title":"Risk and timing of cardiovascular death among patients with myelodysplastic syndromes","volume":"1","author":"Brunner","year":"2017","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.clml.2025.06.020_bib0066","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:18:59Z","timestamp":1762600739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025002368"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization Patterns and Outcomes From Iron Chelation Therapy in Elderly Patients With Myelodysplastic Syndromes: A Population Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}